In patients with renal impairment, rocuronium and sugammadex are the primary choice for reversing neuromuscular blockade, ...

During a live event, Alexander I. Spira, MD, PhD, and participants NGS testing practices and the rationale behind their ...

三代 EGFR-TKIs 耐药后肺癌管理专家共识肺癌是亚太地区最常见的恶性肿瘤。非小细胞肺癌（NSCLC）约占肺癌的 85%。其中，亚洲肺腺癌患者的 EGFR 突变率为 40-60%。第三代 EGFR 酪氨酸激酶抑制剂（EGFR-TKIs）改善了 ...

EGFR-TKI 已成为 EGFR 突变晚期非小细胞肺癌（NSCLC）患者的标准治疗方案[1]，然而，约 2%~5% 的初治 EGFR 突变晚期 NSCLC 患者合并原发 MET 扩增，且接受 EGFR-TKI ...

Glomerular hyperfiltration may increase CVD risks, including myocardial infarction and heart failure, for patients with type ...

Lung cancer is one of the leading causes of cancer mortality worldwide. Non-small cell lung cancer (NSCLC) accounts for about ...

为解决 EGFR 突变肺癌治疗中免疫逃逸和靶点选择难题，The Francis Crick Institute 等机构研究人员开展相关研究。发现治疗中克隆驱动新抗原会丢失，明确 WGD 前后突变特点。该研究为优化肺癌治疗策略提供依据，值得一读。

Ocean Biomedical (OCEA) announced newly published research findings demonstrating the ability of its proprietary cancer immunotherapy ...

从2022年7月19日至2024年4月12日，患者在接受一线治疗期间，连续进行CT复查，结果显示疾病稳定（SD），且无进展生存期（PFS）竟达21个月之久。这对于EGFR突变合并MET扩增的患者而言，显然是一个积极的信号。

Reported encouraging early safety and efficacy data in ongoing dose escalation trial for ORIC-944 in combination with androgen receptor ...

Despite the established links between inflammation and cancer development, the effects of inflammatory signaling on cancer ...